Pyott out after Actavis closes $70B Allergan buyout

Former Allergan CEO David Pyott will not get a seat on the board at Actavis after all, now that their $70 billion merger is done.

Actavis, Allergan Inc.

News Well, Mergers & Acquisitions, Personnel, Pharmaceuticals

read more

from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1MJW8ut